Literature DB >> 20219927

APOBEC3F and APOBEC3G inhibit HIV-1 DNA integration by different mechanisms.

Jean L Mbisa1, Wei Bu, Vinay K Pathak.   

Abstract

APOBEC3F (A3F) and APBOBEC3G (A3G) both are host restriction factors that can potently inhibit human immunodeficiency virus type 1 (HIV-1) replication. Their antiviral activities are at least partially mediated by cytidine deamination, which causes lethal mutations of the viral genome. We recently showed that A3G blocks viral plus-strand DNA transfer and inhibits provirus establishment in the host genome (J. L. Mbisa, R. Barr, J. A. Thomas, N. Vandegraaff, I. J. Dorweiler, E. S. Svarovskaia, W. L. Brown, L. M. Mansky, R. J. Gorelick, R. S. Harris, A. Engelman, and V. K. Pathak, J. Virol. 81:7099-7110, 2007). Here, we investigated whether A3F similarly interferes with HIV-1 provirus formation. We observed that both A3F and A3G inhibit viral DNA synthesis and integration, but A3F is more potent than A3G in preventing viral DNA integration. We further investigated the mechanisms by which A3F and A3G block viral DNA integration by analyzing their effects on viral cDNA processing using Southern blot analysis. A3G generates a 6-bp extension at the viral U5 end of the 3' long terminal repeat (3'-LTR), which is a poor substrate for integration; in contrast, A3F inhibits viral DNA integration by reducing the 3' processing of viral DNA at both the U5 and U3 ends. Furthermore, we demonstrated that a functional C-terminal catalytic domain is more critical for A3G than A3F function in blocking HIV-1 provirus formation. Finally, we showed that A3F has a greater binding affinity for a viral 3'-LTR double-stranded DNA (dsDNA) oligonucleotide template than A3G. Taking these results together, we demonstrated that mechanisms utilized by A3F to prevent HIV-1 viral DNA integration were different from those of A3G, and that their target specificities and/or their affinities for dsDNA may contribute to their distinct mechanisms.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20219927      PMCID: PMC2863843          DOI: 10.1128/JVI.02358-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

1.  An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22.

Authors:  Adam Jarmuz; Ann Chester; Jayne Bayliss; Jane Gisbourne; Ian Dunham; James Scott; Naveenan Navaratnam
Journal:  Genomics       Date:  2002-03       Impact factor: 5.736

2.  Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex.

Authors:  Xianghui Yu; Yunkai Yu; Bindong Liu; Kun Luo; Wei Kong; Panyong Mao; Xiao-Fang Yu
Journal:  Science       Date:  2003-10-16       Impact factor: 47.728

3.  Inhibition of tRNA₃(Lys)-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication.

Authors:  Fei Guo; Shan Cen; Meijuan Niu; Jenan Saadatmand; Lawrence Kleiman
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

4.  Virion-associated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA.

Authors:  Bin Yang; Keyang Chen; Chune Zhang; Sophia Huang; Hui Zhang
Journal:  J Biol Chem       Date:  2007-02-01       Impact factor: 5.157

5.  Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1.

Authors:  Eri Miyagi; Sandrine Opi; Hiroaki Takeuchi; Mohammad Khan; Ritu Goila-Gaur; Sandra Kao; Klaus Strebel
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

6.  A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.

Authors:  Hongzhan Xu; Evguenia S Svarovskaia; Rebekah Barr; Yijun Zhang; Mohammad A Khan; Klaus Strebel; Vinay K Pathak
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-30       Impact factor: 11.205

7.  Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates.

Authors:  Véronique Zennou; Paul D Bieniasz
Journal:  Virology       Date:  2006-02-07       Impact factor: 3.616

8.  APOBEC3G restricts early HIV-1 replication in the cytoplasm of target cells.

Authors:  Jenny L Anderson; Thomas J Hope
Journal:  Virology       Date:  2008-03-04       Impact factor: 3.616

9.  Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation.

Authors:  Kun Luo; Tao Wang; Bindong Liu; Chunjuan Tian; Zuoxiang Xiao; John Kappes; Xiao-Fang Yu
Journal:  J Virol       Date:  2007-04-11       Impact factor: 5.103

10.  APOBEC3G targets human T-cell leukemia virus type 1.

Authors:  Amane Sasada; Akifumi Takaori-Kondo; Kotaro Shirakawa; Masayuki Kobayashi; Aierkin Abudu; Masakatsu Hishizawa; Kazunori Imada; Yuetsu Tanaka; Takashi Uchiyama
Journal:  Retrovirology       Date:  2005-05-19       Impact factor: 4.602

View more
  76 in total

1.  Local sequence targeting in the AID/APOBEC family differentially impacts retroviral restriction and antibody diversification.

Authors:  Rahul M Kohli; Robert W Maul; Amy F Guminski; Rhonda L McClure; Kiran S Gajula; Huseyin Saribasak; Moira A McMahon; Robert F Siliciano; Patricia J Gearhart; James T Stivers
Journal:  J Biol Chem       Date:  2010-10-06       Impact factor: 5.157

2.  Analysis of human APOBEC3H haplotypes and anti-human immunodeficiency virus type 1 activity.

Authors:  Xiaojun Wang; Aierken Abudu; Sungmo Son; Ying Dang; Patrick J Venta; Yong-Hui Zheng
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

Review 3.  Modulation of intracellular restriction factors contributes to methamphetamine-mediated enhancement of acquired immune deficiency syndrome virus infection of macrophages.

Authors:  Xu Wang; Yizhong Wang; Li Ye; Jieliang Li; Yu Zhou; Sinem Sakarcan; Wenzhe Ho
Journal:  Curr HIV Res       Date:  2012-07       Impact factor: 1.581

4.  Inhibition of xenotropic murine leukemia virus-related virus by APOBEC3 proteins and antiviral drugs.

Authors:  Tobias Paprotka; Narasimhan J Venkatachari; Chawaree Chaipan; Ryan Burdick; Krista A Delviks-Frankenberry; Wei-Shau Hu; Vinay K Pathak
Journal:  J Virol       Date:  2010-03-24       Impact factor: 5.103

Review 5.  Studies of endogenous retroviruses reveal a continuing evolutionary saga.

Authors:  Jonathan P Stoye
Journal:  Nat Rev Microbiol       Date:  2012-05-08       Impact factor: 60.633

6.  RIG-I activation inhibits HIV replication in macrophages.

Authors:  Yizhong Wang; Xu Wang; Jieliang Li; Yu Zhou; Wenzhe Ho
Journal:  J Leukoc Biol       Date:  2013-06-06       Impact factor: 4.962

7.  Nuclear import of APOBEC3F-labeled HIV-1 preintegration complexes.

Authors:  Ryan C Burdick; Wei-Shau Hu; Vinay K Pathak
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-18       Impact factor: 11.205

Review 8.  Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all.

Authors:  Belete A Desimmie; Krista A Delviks-Frankenberrry; Ryan C Burdick; DongFei Qi; Taisuke Izumi; Vinay K Pathak
Journal:  J Mol Biol       Date:  2013-11-02       Impact factor: 5.469

9.  APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages.

Authors:  Chawaree Chaipan; Jessica L Smith; Wei-Shau Hu; Vinay K Pathak
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

10.  T cells target APOBEC3 proteins in human immunodeficiency virus type 1-infected humans and simian immunodeficiency virus-infected Indian rhesus macaques.

Authors:  Stéphane Champiat; Keith E Garrison; Rui André Saraiva Raposo; Benjamin J Burwitz; Jason Reed; Ravi Tandon; Vanessa A York; Laura P Newman; Francesca A Nimityongskul; Nancy A Wilson; Rafael R Almeida; Jeffrey N Martin; Steven G Deeks; Michael G Rosenberg; Andrew A Wiznia; Gerald E Spotts; Christopher D Pilcher; Fredrick M Hecht; Mario A Ostrowski; Jonah B Sacha; Douglas F Nixon
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.